High doses of aspirin tied to poor Brilinta response

Seeking the data needed to remove the regulatory cloud hovering above the potential blockbuster Brilinta, a new analysis of a late-stage study shows that heart patients taking high doses of aspirin did worse than the patients on low doses. AstraZeneca will use this new analysis in its response to the FDA, which had been troubled to see data indicating that patients in the U.S. did not do as well on Brilinta as the European arm of the study. One possible reason for that, AstraZeneca had noted, could be the higher doses of aspirin used in the U.S. "While the regional interaction could arise from chance alone, two independently performed analyses identified a statistical interaction with aspirin maintenance dose that may explain the regional difference," said the researchers. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.